Precautions and warnings

This product contains soya oil and egg lecithin, which can sometimes cause allergic reactions. People allergic to peanuts may also react to soya-bean. Fat metabolism can be affected in people with kidney problems, uncontrolled diabetes, pancreatitis, liver problems, metabolic disorders, or sepsis, so Fatisol should be given carefully. There is a strong link between C-reactive protein levels and Fatisol clumping in very sick patients.

Fatisol should be used cautiously in newborns and premature babies, especially those with high bilirubin levels or suspected lung pressure problems. In low birthweight babies, the risk of giving lipid infusions may be higher than any benefit, as their defenses against infection may be weaker. In infants, infections and treatment with heparin can also reduce the body’s ability to process fat. For newborns, especially premature ones, getting long-term nutrition through a vein, it’s important to regularly check their platelet count, liver function, and blood fat levels.

Use in Pregnancy & Breastfeeding: The safety of this product during pregnancy and breastfeeding has not been confirmed, so it should be used carefully in these situations.

Contraindications

This medication should not be used in people who have serious problems with fat metabolism, such as those with severe liver damage or experiencing acute shock. It is also not suitable for anyone who is allergic to eggs, soy, peanuts, or any of the other ingredients in the medication.

Mode of actions

These solutions are isotonic and can be given through either a central or peripheral vein. FatisolTM is specially made as a concentrated energy source to be used along with carbohydrates and amino acids in parenteral nutrition. It is isotonic, supplies basic phosphate needs, and provides vitamin E.

Dosage & Administration

Total Parenteral nutrition: As a part of TPN, administer IV via a peripheral vein or by central venous catheter. Fat emulsion should comprise no more than 60% of the patient's total caloric intake, with carbohydrates and amino acids comprising the remaining 40% or more of caloric intake.

Adult: Initial infusion rate is 1ml/min for the first 15 to 30 mins. If no adverse reactions occur, the infusion rate can be increased to 2 ml/min. Infuse only 500 ml the first day and increase dose the following day. Do not exceed a daily dosage of 2.5 g/kg.
Children: Initial infusion rate is 0.1ml/min for the first 10 to 15 mins. If no adverse reactions occur, the infusion rate can be increased to 1g/kg in 4 hours. Do not exceed a daily dosage of 3 g/kg.
Infants: Starts at 0.5g/kg/24 hours and may be increased in relation to the infant's ability to eliminate fat. The maximum recommended dosage is 3g/kg/24 hours.
Fatty acid deficiency: To correct EFAD, supply 8% to 10% of the caloric intake by IV fat emulsion to provide an adequate amount of linoleic acid.

Pregnancy & Lactation

FDA has not yet classified this medicine into a specified pregnancy category. Although there is no enough evidence that taking this medicine during you are pregnant is harmful.

Discuss with your doctor if you are trying to get pregnant while taking this medicine too.

If you do become pregnant while you are taking this medicine, you should continue to take it and contact with your doctors as quickly as possible. They can assist you to decide whether or not to keep taking this medicine. If you abandon taking this medicine and become sick, this would be more pernicious to your child than staying on the medication.


There is no specific information about whether this medicine is passed on to the baby through breast milk. During this medication, if your baby becomes very sleepy, restless, fatigued, exhibit feeding problems, stop breastfeeding and talk to your doctors very quickly.

Pack Size & Price